Transgender hormone therapy (female-to-male) to individuals taking bioidentical hormones in the form of testosterone (including esters) and do not apply to those taking synthetic AAS (e.g., nandrolone) or dihydrotestosterone. Transgender hormone therapy (female-to-male) Transgender hormone therapy of the female-to-male (FTM) type, also known as masculinizing hormone therapy, is a form of hormone therapy and sex reassignment therapy which is used to change the secondary sexual characteristics of transgender people from feminine (or androgynous) to masculine. It is one of two types of transgender hormone therapy (the other being male-to-female), and is predominantly used to treat transgender men and other transmasculine individuals. Some intersex people
Fraternal birth order and male sexual orientation fraternal birth order (or the underlying variable it reflects) may be the first universal factor to be identified in development of same-sex attraction in males. Bearman and Brückner (2002) argued that studies showing a fraternal birth order effect have used nonrepresentative samples and/or indirect reports on siblings' sexual orientation. Their analysis, focusing on opposite-sex twins, did not find an association "between same-sex attraction and number of older siblings, older brothers, or older sisters". A study by Francis (2008), using the same Add Health survey but with broader analysis, saw a very weak correlation of male same-sex attraction with having multiple